Botulinum toxin type A treatment in children with cerebral palsy: Evaluation of treatment success or failure by means of goal attainment scaling

European Journal of Paediatric Neurology

Volumn 16, Issue 3, 2012, Pages 229-236

  Desloovere, Kaat ^a,b   Schörkhuber, Verena ^a   Fagard, Katrien ^a   Van Campenhout, Anja ^a,b   De Cat, Jos ^a   Pauwels, Petra ^a   Ortibus, Els ^a   De Cock, Paul ^a   Molenaers, Guy ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Botulinum toxin type A; Cerebral palsy; Goal attainment scale

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; CEREBRAL PALSY; CHILD; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GOAL ATTAINMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; BOTULINUM TOXINS, TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; MALE; NEUROMUSCULAR AGENTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84859940194     PISSN: 10903798     EISSN: 15322130     Source Type: Journal    
DOI: 10.1016/j.ejpn.2010.09.006     Document Type: Article

References (27)

1. Koman LA, Smith BP, Balkrishnan R. Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin. Paediatr Drugs 2003;5:11-23. (Pubitemid 36127021)
2. Gage JR, editor. The treatment of gait problems in cerebral palsy. London: Mac Keith Press; 2004.
3. Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 1997;4:15-22.
4. Corry IS, Cosgrove AP, Duffy CM, McNeill S, Taylor TC, Graham HK. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomised prospective trial. J Pediatr Orthop 1998;18:304-11. (Pubitemid 28212938)
5. Wissel J, Heinen F, Schenkel A, Doll B, Ebersbach G, Müller J, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double-blind study of "high-dose" versus "lowdose" treatment. Neuropediatrics 1999;30:120-4. (Pubitemid 29366681)
6. Zelnik N, Giladi N, Goikhman I, Keren G, Moris R, Honigman S. The role of Botulinum toxin in the treatment of lower limb spasticity in children with cerebral palsy e a pilot study. Isr J Med Sci 1997;33:129-33. (Pubitemid 27334213)
7. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999;10:1-9. (Pubitemid 29406176)
8. Koman LA, Mooney JF, Smith PB, Walker F, Leon JM. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 2000;20:108-15. (Pubitemid 30013408)
9. Eames NW, Baker R, Hill N, Graham K, Taylor T, Cosgrove A. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 1999;41:226-32. (Pubitemid 29209924)
10. Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006;21:189-92. (Pubitemid 43891142)
11. Dressler D. Clinical features of antibody-induced complete secondary failure of botulinumtoxin therapy. Eur Neurol 2002; 48:26-9.
12. Bottos M, Benedetti MG, Salucci P, Gasparroni V, Giannini S. Botulinum toxin with and without casting in ambulant children with spastic diplegia: a clinical and functional assessment. Dev Med Child Neurol 2003;45:758-62. (Pubitemid 37304065)
13. Desloovere K, Molenaers G, Jonkers I, De Cat J, De Borre L, Nijs J, et al. A randomised study of combined Botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 2001;8:75-87. (Pubitemid 33757693)
14. Scholtes VA, Dallmeijer AJ, Knol DL, Speth LA, Maathuis CG, Jongerius PH, et al. The combined effect of lower-limb multilevel botulinum toxin type A and comprehensive rehabilitation on mobility in children with cerebral palsy: a randomized clinical trial. Arch Phys Med Rehabil 2006;87: 1551-8. (Pubitemid 44821066)
15. Molenaers G, Schörkhuber V, Fagard K, Van Campenhout A, De Cat J, Pauwels P, et al. Long-term use of botulinum toxin type A in children with cerebral palsy: treatment consistency. Eur J Paediatr Neurol 2009;13:421-9.
16. Molenaers G, Desloovere K, Eyssen M, De Cat J, Jonkers I, De Cock P. Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol 1999;6:51-7.
17. Randall M, Johnson L, Reddihough D. The Melbourne assessment of unilateral upper limb function. Melbourne: Arena Printing; 1999.
18. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;39:214-23. (Pubitemid 27226331)
19. Kiresuk TJ, Smith A, Cardillo JE. Goal attainment scaling: applications, theory and measurement. Hillsdale, New Jersey: Lawrence Erlbaum Associates; 1994.
20. Palisano RJ. Validity of goal attainment scaling in infants with motor delays. Phys Ther 1993;73:651-60. (Pubitemid 23308025)
21. Shefler G, Canetti L, Wiseman H. Psychometric properties of goal-attainment scaling in the assessment of Mann's timelimited psychotherapy. J Clin Psychol 2001;57:971-9. (Pubitemid 32566011)
22. Rushton P, Miller W. Goal attainment scaling in the rehabilitation of patients with lower-extremity amputations: a pilot study. Arch Phys Med Rehabil 2002;83:771-5. (Pubitemid 34721475)
23. Herrmann J, Geth K, Mall V, Bigalke H, Schulte Mönting J, Linder M, et al. Clinical impact of antibody formation to botulinum toxin A in children. Ann Neurol 2004;55:732-5. (Pubitemid 38544335)
24. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, et al. Botulinum toxin type A neuromuscular blockade in the treatment of equines foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001;108:1062-71. (Pubitemid 33021177)
25. Linder M, Schindler G, Michaelis U, Stein S, Kirschner J, Mall V, et al. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1- year follow-up using gross motor function measure. Eur J Neurol 2001;8:120-6. (Pubitemid 33757697)
26. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, et al. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. Eur J Paediatr Neurol 2010;14:45-66. Review.
27. Molenaers G, Van Campenhout A, Fagard K, De Cat J, Desloovere K. The use of botulinum toxin A in children with cerebral palsy, with a focus on the lower limb. J Child Orthop 2010;4:183-95.